In/IN
Silico/NN
Docking/JJ
to/TO
Explicate/VB
Interface/NN
between/IN
Plant-Originated/JJ
Inhibitors/NNS
and/CC
E6/NN
Oncogenic/JJ
Protein/NN
of/IN
Highly/RB
Threatening/VBG
Human/JJ
Papillomavirus/NN
18/CD
./.
====================
The/DT
leading/VBG
cause/VBP
of/IN
cancer/NN
mortality/NN
globally/RB
amongst/IN
the/DT
women/NNS
is/VBZ
due/JJ
to/TO
human/JJ
papillomavirus/NN
(/(
HPV/NN
)/)
infection/NN
./.
====================
There/EX
is/VBZ
need/VBN
to/TO
explore/VB
anti-cancerous/JJ
drugs/NNS
against/IN
this/DT
life-threatening/JJ
infection/NN
./.
====================
Traditionally/RB
,/,
different/JJ
natural/JJ
compounds/NNS
such/JJ
as/IN
withaferin/IN
A/DT
,/,
artemisinin/NN
,/,
ursolic/JJ
acid/NN
,/,
ferulic/JJ
acid/NN
,/,
(/(
-/:
)/)
-epigallocatechin-3-gallate/JJ
,/,
berberin/IN
,/,
resveratrol/NN
,/,
jaceosidin/NN
,/,
curcumin/NN
,/,
gingerol/JJ
,/,
indol-3-carbinol/NNP
,/,
and/CC
silymarin/NN
have/VBP
been/VBN
used/VBN
as/IN
hopeful/JJ
source/NN
of/IN
cancer/NN
treatment/NN
./.
====================
These/DT
natural/JJ
inhibitors/NNS
have/VBP
been/VBN
shown/VBN
to/TO
block/VB
HPV/NN
infection/NN
by/IN
different/JJ
researchers/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
explored/VBD
these/DT
natural/JJ
compounds/NNS
against/IN
E6/NN
oncoprotein/NN
of/IN
high/JJ
risk/NN
HPV18/NN
,/,
which/WDT
is/VBZ
known/VBN
to/TO
inactivate/VB
tumor/NN
suppressor/NN
p53/NN
protein/NN
./.
====================
E6/CD
,/,
a/DT
high/JJ
throughput/NN
protein/NN
model/NN
of/IN
HPV18/NN
,/,
was/VBD
predicted/VBN
to/TO
anticipate/JJ
the/DT
interaction/NN
mechanism/NN
of/IN
E6/NN
oncoprotein/NN
with/IN
these/DT
natural/JJ
inhibitors/NNS
using/VBG
structure-based/JJ
drug/NN
designing/VBG
approach/NN
./.
====================
Docking/VBG
analysis/NN
showed/VBD
the/DT
interaction/NN
of/IN
these/DT
natural/JJ
inhibitors/NNS
with/IN
p53/NN
binding/NN
site/NN
of/IN
E6/NN
protein/NN
residues/NNS
108-117/CD
(/(
CQKPLNPAEK/NN
)/)
and/CC
help/VB
reinstatement/JJ
of/IN
normal/JJ
p53/NN
functioning/VBG
./.
====================
Further/RB
,/,
docking/NN
analysis/NN
besides/VBZ
helping/VBG
in/IN
silico/NN
validations/NNS
of/IN
natural/JJ
compounds/NNS
also/RB
helped/VBD
elucidating/VBG
the/DT
molecular/JJ
mechanism/NN
of/IN
inhibition/NN
of/IN
HPV/NN
oncoproteins/NNS
./.
====================
Human/JJ
papillomavirus/NN
(/(
HPV/NN
)/)
accounts/VBZ
for/IN
5.2/CD
%/NN
of/IN
all/DT
cancers/NNS
globally/RB
./.
====================
Besides/RB
cervical/JJ
cancer/NN
HPV/NN
also/RB
causes/VBZ
a/DT
subset/NN
of/IN
anogenital/JJ
,/,
head/RB
and/CC
neck/NN
cancers/NNS
[/(
12/CD
]/)
./.
====================
Most/JJS
of/IN
the/DT
cancer/NN
mortality/NN
in/IN
women/NNS
worldwide/NN
is/VBZ
due/JJ
to/TO
cervical/JJ
cancer/NN
with/IN
an/DT
estimated/VBN
527,624/CD
new/JJ
cases/NNS
and/CC
265,653/CD
annual/JJ
mortality/NN
[/(
3/CD
]/)
./.
====================
Among/IN
more/RBR
than/IN
200/CD
HPV/NN
types/NNS
,/,
mostly/RB
HPV/NN
type/NN
18/CD
and/CC
16/CD
are/VBP
the/DT
main/JJ
cause/JJ
of/IN
cervical/JJ
cancer/NN
i.e./FW
,/,
15.7/CD
%/NN
and/CC
62.6/CD
%/NN
,/,
respectively/RB
[/(
4/CD
]/)
./.
====================
Further/RB
,/,
HPV/NN
16/CD
and/CC
18/CD
are/VBP
also/RB
associated/VBN
with/IN
penile/JJ
cancer/NN
(/(
63/CD
%/NN
-80/CD
%/NN
)/)
,/,
vulva/vaginal/JJ
cancers/NNS
(/(
80/CD
%/NN
-86/CD
%/NN
)/)
,/,
anal/JJ
cancer/NN
(/(
93/CD
%/NN
)/)
,/,
oropharyngeal/JJ
cancers/NNS
(/(
89/CD
%/NN
-95/CD
%/NN
)/)
,/,
etc/JJ
./.
====================
[/(
5/CD
]/)
./.
====================
Thus/RB
,/,
these/DT
two/CD
HPV/NN
types/NNS
are/VBP
the/DT
main/JJ
targets/NNS
for/IN
designing/VBG
anti/JJ
cancer/NN
drugs/NNS
./.
====================
The/DT
HPV/NN
onco-proteins/NNS
E6/NN
and/CC
E7/NN
,/,
have/VBP
been/VBN
reported/VBN
to/TO
interact/VB
with/IN
tumor/NN
suppressor/NN
proteins/NNS
p53/NN
and/CC
pRb/NN
respectively/RB
[/(
6/CD
]/)
./.
====================
Both/DT
p53/NN
and/CC
pRb/NN
act/VBP
as/IN
negative/JJ
regulator/NN
of/IN
cell/NN
cycle/NN
and/CC
inhibit/VBP
G0-G1/NN
and/CC
G1-S/NN
phase/NN
transitions/NNS
./.
====================
These/DT
interactions/NNS
apparently/RB
play/VBP
important/JJ
roles/NNS
in/IN
the/DT
induction/NN
of/IN
cell/NN
immortality/NN
./.
====================
The/DT
importance/NN
of/IN
p53-mediated/JJ
apoptosis/NN
has/VBZ
been/VBN
recognized/VBN
in/IN
terms/NNS
of/IN
maintaining/VBG
homeostasis/NN
and/CC
preventing/VBG
neoplastic/JJ
transformation/NN
./.
====================
E6/CD
forms/NNS
a/DT
ternary/JJ
complex/NN
with/IN
p53/NN
and/CC
E6/NN
associated/VBN
protein/NN
(/(
E6AP/NN
)/)
resulting/VBG
in/IN
the/DT
degradation/NN
of/IN
p53/NN
via/IN
ubiquitination/NN
pathway/NN
[/(
7/CD
]/)
./.
====================
Although/IN
HPV/NN
has/VBZ
been/VBN
known/VBN
to/TO
be/VB
a/DT
causative/JJ
agent/NN
for/IN
cervical/JJ
cancer/NN
for/IN
more/RBR
than/IN
three/CD
decades/NNS
,/,
the/DT
effective/JJ
treatment/NN
against/IN
HPV/NN
infection/NN
is/VBZ
yet/RB
to/TO
be/VB
established/VBN
[/(
8/CD
]/)
./.
====================
Many/JJ
natural/JJ
plant/NN
origin/NN
compounds/NNS
have/VBP
been/VBN
identified/VBN
as/IN
promising/JJ
sources/NNS
of/IN
drugs/NNS
for/IN
treatment/NN
and/CC
prevention/NN
of/IN
cancer/NN
in/IN
the/DT
recent/JJ
years/NNS
[/(
910/CD
]/)
./.
====================
Indole-3-carbinol/RB
,/,
an/DT
active/JJ
ingredient/JJ
of/IN
cabbage/JJ
,/,
broccoli/FW
,/,
cauliflower/JJR
,/,
brussels/NNS
sprouts/NNS
,/,
etc/JJ
./.
====================
was/VBD
reported/VBN
with/IN
anti-estrogenic/JJ
properties/NNS
in/IN
cervical/JJ
cells/NNS
[/(
11/CD
]/)
./.
====================
Ursolic/JJ
acid/NN
having/VBG
anti-mutagenic/JJ
nature/NN
has/VBZ
the/DT
potential/JJ
to/TO
induce/VB
apoptosis/NN
in/IN
tumor/NN
cells/NNS
as/IN
well/RB
as/IN
to/TO
prevent/VB
malignant/JJ
transformation/NN
of/IN
normal/JJ
cells/NNS
[/(
12/CD
]/)
./.
====================
Resveratrol/NN
is/VBZ
a/DT
polyphenol/JJ
isolated/VBN
from/IN
the/DT
grapes/NNS
skin/NN
,/,
shown/VBN
to/TO
alter/VB
both/CC
cell/NN
cycle/NN
progression/NN
and/CC
the/DT
cytotoxic/JJ
response/NN
to/TO
ionizing/VBG
radiation/NN
in/IN
cervical/JJ
tumor/NN
cell/NN
lines/NNS
[/(
13/CD
]/)
./.
====================
Curcumin/NN
is/VBZ
cytotoxic/JJ
to/TO
cervical/JJ
cancer/NN
cells/NNS
in/IN
a/DT
concentration/NN
dependent/JJ
and/CC
time-dependent/JJ
manner/NN
and/CC
the/DT
cytotoxicity/NN
was/VBD
higher/JJR
in/IN
HPV/NN
infected/JJ
cells/NNS
./.
====================
It/PRP
down/RB
regulates/VBZ
both/CC
serine/NN
kinase/NN
AKT/nuclear/JJ
factor/NN
κB/NN
pathway/NN
by/IN
sensitizing/VBG
cancer/NN
cells/NNS
[/(
14/CD
]/)
./.
====================
It/PRP
also/RB
down/RB
regulates/VBZ
the/DT
expression/NN
of/IN
HPV/NN
oncoproteins/NNS
,/,
resulting/VBG
in/IN
loss/NN
of/IN
the/DT
transforming/VBG
phenotype/NN
and/CC
the/DT
cessation/NN
of/IN
cellular/JJ
growth/NN
./.
====================
Singh/IN
and/CC
Singh/JJ
[/(
15/CD
]/)
explored/VBD
other/JJ
molecular/JJ
mechanisms/NNS
exerted/VBD
by/IN
curcumin/NN
in/IN
cervical/JJ
cancer/NN
cells/NNS
,/,
showing/VBG
that/IN
it/PRP
inhibits/VBZ
telomerase/NN
activity/NN
,/,
RAS/NN
and/CC
ERK/NN
signaling/VBG
pathway/NN
,/,
cyclin/NN
D1/NN
,/,
cyclooxygenase/NN
2/CD
,/,
and/CC
inducible/JJ
nitric/JJ
oxide/NN
synthase/NN
activity/NN
[/(
15/CD
]/)
./.
====================
Ginger/IN
(/(
active/JJ
ingredient/JJ
,/,
gingerol/JJ
)/)
is/VBZ
a/DT
natural/JJ
dietary/NN
component/NN
,/,
which/WDT
has/VBZ
antioxidant/JJ
and/CC
anticarcinogenic/JJ
properties/NNS
and/CC
its/PRP$
supplementation/NN
has/VBZ
shown/VBN
to/TO
suppress/VB
colon/NN
carcinogenesis/NN
[/(
16/CD
]/)
./.
====================
Jaceosidin/NN
,/,
a/DT
active/JJ
ingredient/JJ
of/IN
Artemisia/NN
argyi/NN
,/,
reported/VBD
to/TO
inhibit/VB
the/DT
binding/NN
between/IN
oncoproteins/NNS
and/CC
tumor/NN
suppressors/NNS
p53/NN
[/(
17/CD
]/)
./.
====================
Through/IN
the/DT
post-attachment/JJ
heparan/NN
sulfate-independent/JJ
effect/NN
,/,
it/PRP
is/VBZ
reported/VBN
that/IN
carrageenan/NN
block/VBP
HPV/NN
infection/NN
by/IN
preventing/VBG
the/DT
binding/NN
of/IN
HPV/NN
virions/NNS
to/TO
cells/NNS
[/(
18/CD
]/)
./.
====================
Due/IN
to/TO
the/DT
antiviral/JJ
and/CC
antitumor/JJ
properties/NNS
of/IN
(/(
-/:
)/)
-epigallocatechin-3-gallate/NN
(/(
EGCG/NN
)/)
,/,
it/PRP
was/VBD
found/VBN
effective/JJ
in/IN
HPV/NN
patients/NNS
with/IN
infected/JJ
cervical/JJ
lesions/NNS
[/(
19/CD
]/)
./.
====================
EGCG/NN
also/RB
reported/VBD
as/IN
an/DT
effective/JJ
inhibitor/NN
of/IN
E6/E7/NN
proteins/NNS
due/JJ
to/TO
its/PRP$
inhibitory/JJ
effect/NN
on/IN
the/DT
growth/NN
of/IN
HeLa/NN
(/(
HPV18/CD
positive/JJ
)/)
and/CC
CaSki/FW
(/(
HPV16/NN
positive/JJ
)/)
cells/NNS
in/IN
a/DT
time/NN
and/CC
concentration/NN
dependent/JJ
manner/NN
[/(
20/CD
]/)
./.
====================
Mahata/NNS
et/FW
al/JJ
./.
====================
[/(
21/CD
]/)
studied/VBN
the/DT
effect/NN
of/IN
berberine/JJ
on/IN
HPV16/NN
and/CC
HPV18/NN
positive/JJ
cervical/JJ
cancer/NN
cell/NN
line/NN
,/,
and/CC
observed/VBN
that/IN
it/PRP
can/MD
effectively/RB
target/NN
both/CC
the/DT
host/NN
and/CC
viral/JJ
factors/NNS
responsible/JJ
for/IN
development/NN
of/IN
cervical/JJ
cancer/NN
through/IN
inhibition/NN
of/IN
viral/JJ
oncoproteins/NNS
E6/NN
and/CC
E7/NN
expression/NN
./.
====================
An/DT
in/IN
vitro/FW
study/NN
conducted/VBD
by/IN
Karthikeyan/JJ
et/FW
al/JJ
./.
====================
[/(
22/CD
]/)
reported/VBD
the/DT
radiosensitizing/JJ
potential/JJ
of/IN
ferulic/JJ
acid/NN
(/(
a/DT
natural/JJ
phenolic/JJ
acid/NN
)/)
on/IN
human/JJ
cervical/JJ
cancer/NN
cell/NN
lines/NNS
(/(
HeLa/NN
and/CC
ME-180/CD
)/)
[/(
22/CD
]/)
./.
====================
Silymarin/NN
,/,
an/DT
active/JJ
ingredient/JJ
contained/VBD
in/IN
the/DT
seeds/VBZ
of/IN
the/DT
milk/NN
thistle/JJ
plant/JJ
,/,
reported/VBD
to/TO
inhibit/VB
cervical/JJ
cancer/NN
cell/NN
[/(
23/CD
]/)
./.
====================
Hu/NNP
et/FW
al/JJ
./.
====================
[/(
24/CD
]/)
evaluated/VBD
the/DT
anti-tumor/JJ
effect/NN
of/IN
dihydroartemisinin/NN
(/(
DHA/NN
)/)
,/,
an/DT
artemisinin/NN
derivative/JJ
on/IN
HeLa/NN
and/CC
Caski/NN
cervical/JJ
cancer/NN
cells/NNS
and/CC
found/VBD
that/IN
DHA/NN
treatment/NN
caused/VBD
a/DT
considerable/JJ
inhibition/NN
of/IN
tumor/NN
development/NN
[/(
24/CD
]/)
./.
====================
The/DT
active/JJ
compound/NN
of/IN
Withania/NN
somnifera/RB
i.e./FW
,/,
withaferin/IN
A/NN
(/(
WA/NN
)/)
has/VBZ
reported/VBN
to/TO
have/VB
antitumor/JJ
,/,
antiangiogenic/JJ
and/CC
radiosensitizing/JJ
activity/NN
[/(
2526/CD
]/)
./.
====================
Through/IN
in/IN
vitro/FW
and/CC
in/IN
vivo/FW
study/NN
Munagala/NN
et/FW
al/JJ
./.
====================
[/(
27/CD
]/)
demonstrated/VBD
the/DT
effective/JJ
inhibition/NN
of/IN
proliferation/NN
of/IN
cervical/JJ
cancer/NN
cells/NNS
by/IN
WA/NN
./.
====================
Further/RB
,/,
they/PRP
showed/VBD
the/DT
down/JJ
regulation/NN
of/IN
HPV/NN
E6/NN
and/CC
restoration/NN
of/IN
p53/NN
pathway/NN
by/IN
WA/NN
[/(
27/CD
]/)
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
explicate/VBP
the/DT
atomic/JJ
interaction/NN
between/IN
plant-originated/JJ
ligands/NNS
and/CC
high/JJ
risk/NN
HPV18/NN
E6/NN
oncogenic/JJ
protein/NN
./.
====================
This/DT
study/NN
comprises/VBZ
of/IN
protein/NN
structure/NN
modeling/VBG
of/IN
HPV18/NN
E6/NN
protein/NN
employing/VBG
Phyre2/NN
server/RB
followed/VBN
by/IN
structural/JJ
refinement/JJ
and/CC
energy/NN
minimization/NN
by/IN
Yet/RB
Another/DT
Scientific/JJ
Artificial/JJ
Reality/NN
Application/NN
(/(
YASARA/NN
)/)
energy/NN
minimization/NN
server/RB
./.
====================
To/TO
analyze/VB
the/DT
molecular/JJ
interaction/NN
between/IN
HPV18/CD
E6/NN
onco-protein/NN
with/IN
natural/JJ
ligands/NNS
,/,
AutoDock4.2/NN
tool/NN
was/VBD
used/VBN
in/IN
this/DT
study/NN
./.
====================
Hardware/JJ
and/CC
software/JJ
====================
Dell/NN
Workstation/NN
with/IN
Windows/NNS
operating/VBG
system/NN
having/VBG
500/CD
GB/NN
hard/VBP
drive/VBP
,/,
6/CD
GB/NN
RAM/NN
and/CC
2.26/CD
GHz/NN
processor/NN
was/VBD
employed/VBN
in/IN
this/DT
study/NN
./.
====================
Different/JJ
online/JJ
resources/VBZ
and/CC
AutoDock/NN
4.2/CD
were/VBD
used/VBN
in/IN
this/DT
study/NN
./.
====================
HPV18/CD
E6/NN
protein/NN
====================
As/IN
HPV18/NN
E6/NN
protein/NN
was/VBD
selected/VBN
as/IN
drug/NN
target/NN
in/IN
this/DT
study/NN
,/,
its/PRP$
amino/NN
acid/NN
sequence/NN
(/(
GenBank/NN
ID/NN
:/:
NP_040310.1/NN
)/)
was/VBD
retrieved/VBN
from/IN
NCBI/NN
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov//JJ
)/)
./.
====================
Prediction/NN
of/IN
protein/NN
structure/NN
and/CC
its/PRP$
validation/NN
====================
Phyre2/NN
server/RB
[/(
28/CD
]/)
was/VBD
employed/VBN
for/IN
modeling/VBG
of/IN
the/DT
tertiary/JJ
structure/NN
of/IN
E6/NN
protein/NN
followed/VBN
by/IN
energy/NN
minimization/NN
using/VBG
YASARA/NN
Energy/NN
Minimization/NN
Server/NN
[/(
29/CD
]/)
./.
====================
Further/RB
the/DT
protein/NN
three/CD
dimension/NN
structure/NN
in/IN
pdb/NN
format/IN
was/VBD
subjected/VBN
to/TO
SCWRL4.0/CD
software/JJ
[/(
30/CD
]/)
for/IN
protein/NN
side/JJ
chain/NN
modeling/VBG
before/IN
docking/NN
./.
====================
Procheck/NN
[/(
31/CD
]/)
,/,
ProSA-web/NN
[/(
32/CD
]/)
,/,
and/CC
ProQ/NN
[/(
33/CD
]/)
server/RB
were/VBD
used/VBN
for/IN
assessing/VBG
the/DT
model/NN
reliability/NN
which/WDT
further/RB
verified/VBN
by/IN
ERRAT/NN
server/RB
[/(
34/CD
]/)
./.
====================
Ligand/NN
preparation/NN
and/CC
protein-ligand/NN
docking/NN
====================
Chemical/JJ
structures/NNS
along/IN
with/IN
Chemical/JJ
Abstracts/NNS
Service/NN
(/(
CAS/NN
)/)
registry/NN
number/NN
of/IN
12/CD
natural/JJ
compounds/NNS
reported/VBD
in/IN
literature/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
(/(
artemisinin/NN
,/,
WA/NN
,/,
ursolic/JJ
acid/NN
,/,
ferulic/JJ
acid/NN
,/,
EGCG/NN
,/,
berberin/IN
,/,
resveratrol/NN
,/,
jaceosidin/NN
,/,
curcumin/NN
,/,
gingerol/JJ
,/,
indol-3-carbinol/NNP
,/,
and/CC
silymarin/NN
)/)
,/,
were/VBD
retrieved/VBN
from/IN
PubChem/JJ
database/NN
(/(
Table/JJ
1/CD
)/)
[/(
35/CD
]/)
./.
====================
Receptor/NN
molecules/NNS
(/(
HPV18/CD
E6/NN
)/)
was/VBD
prepared/VBN
in/IN
AutoDock/NN
4.2/CD
program/NN
[/(
36/CD
]/)
and/CC
docking/NN
studies/NNS
were/VBD
performed/VBN
as/IN
per/IN
the/DT
standard/JJ
methodology/NN
for/IN
protein-ligand/CC
docking/NN
used/VBN
by/IN
Kumar/JJ
et/FW
al/JJ
./.
====================
[/(
37/CD
]/)
./.
====================
Visualization/NN
====================
ADT/NN
tool/NN
and/CC
PyMol/NN
molecular/JJ
graphics/NNS
system/NN
(/(
http/NN
:/:
//www.pymol.org/JJ
)/)
were/VBD
used/VBN
for/IN
visualizing/VBG
the/DT
structure/NN
files/NNS
./.
====================
Protein/NN
structure/NN
prediction/NN
and/CC
validation/NN
====================
There/EX
are/VBP
158/CD
amino/NN
acids/NNS
in/IN
the/DT
protein/NN
sequence/NN
of/IN
HPV18/NN
E6/NN
protein/NN
./.
====================
As/IN
the/DT
experimentally/RB
determined/VBN
tertiary/JJ
structure/NN
of/IN
E6/NN
was/VBD
not/RB
available/JJ
,/,
Phyre2/NN
server/RB
was/VBD
used/VBN
to/TO
predict/VB
its/PRP$
three/CD
dimensional/JJ
structure/NN
./.
====================
During/IN
structure/NN
prediction/NN
,/,
crystal/JJ
structure/NN
of/IN
C/NN
chain/NN
of/IN
full-length/JJ
HPV/NN
oncoprotein/NN
e62/NN
in/IN
complex/NN
with/IN
lxxll/JJ
peptide/NN
of/IN
ubiquitin/NN
ligase/NN
E6AP/NN
(/(
PDB/NN
ID/NN
,/,
4GIZ/NN
)/)
was/VBD
taken/VBN
as/IN
structural/JJ
template/NN
by/IN
Phyre2/NN
server/RB
./.
====================
There/EX
was/VBD
query/RB
coverage/NN
of/IN
89/CD
%/NN
and/CC
identities/VBZ
of/IN
57/CD
%/NN
observed/VBN
between/IN
target-template/NN
alignment/NN
./.
====================
Upon/IN
structural/JJ
refinement/JJ
of/IN
predicted/VBN
structure/NN
by/IN
YASARA/NN
Energy/NN
Minimization/NN
Server/NN
,/,
the/DT
total/JJ
energy/NN
of/IN
refined/VBN
structure/NN
was/VBD
observed/VBN
to/TO
be/VB
-19,732.64/CD
kcal/mol/NN
(/(
score/RB
,/,
0.07/CD
)/)
,/,
whereas/IN
it/PRP
was/VBD
as/IN
166,485.03/CD
kcal/mol/NN
(/(
score/RB
,/,
-0.55/CD
)/)
prior/RB
to/TO
energy/NN
minimization/NN
./.
====================
Upon/IN
Procheck/NN
analysis/NN
,/,
99.2/CD
%/NN
residues/NNS
of/IN
the/DT
refined/VBN
model/NN
(/(
Fig/NN
./.
====================
2A/NN
)/)
were/VBD
found/VBN
in/IN
most/JJS
favourable/JJ
region/NN
and/CC
additional/JJ
allowed/VBD
regions/NNS
and/CC
only/RB
0.8/CD
%/NN
(/(
Ser59/NN
)/)
residue/NN
in/IN
situated/JJ
generously/RB
allowed/VBD
region/NN
,/,
whereas/IN
not/RB
a/DT
single/JJ
residue/NN
observed/VBN
in/IN
the/DT
disallowed/JJ
region/NN
of/IN
Ramachandran/NN
plot/NN
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
The/DT
compatible/JJ
Z/NN
score/NN
(/(
Fig/NN
./.
====================
2C/NN
)/)
value/NN
was/VBD
observed/VBN
to/TO
be/VB
-4.46/CD
by/IN
ProSA-web/NN
evaluation/NN
,/,
which/WDT
is/VBZ
quite/RB
well/RB
within/IN
the/DT
native/JJ
conformations/NNS
range/NN
of/IN
crystal/JJ
structures/NNS
[/(
31/CD
]/)
./.
====================
The/DT
residue/NN
energy/NN
of/IN
the/DT
refined/VBN
model/NN
were/VBD
observed/VBN
to/TO
be/VB
largely/RB
negative/JJ
(/(
Fig/NN
./.
====================
2D/CD
)/)
./.
====================
The/DT
Protein/NN
Quality/NN
Predictor/NN
(/(
ProQ/NN
)/)
tool/NN
predict/VBP
the/DT
LG/NN
score/RB
of/IN
2.205/CD
for/IN
HPV18/NN
E6/NN
protein/NN
model/NN
,/,
implying/VBG
high/JJ
precision/NN
of/IN
the/DT
modeled/JJ
structure/NN
as/IN
ProQ/NN
LG/NN
score/RB
of/IN
more/RBR
than/IN
1.5/CD
is/VBZ
essential/JJ
for/IN
signifying/VBG
that/DT
a/DT
predicted/VBN
structure/NN
is/VBZ
of/IN
fairly/RB
good/JJ
quality/NN
[/(
33/CD
]/)
./.
====================
The/DT
overall/JJ
quality/NN
factor/NN
is/VBZ
predicted/VBN
to/TO
be/VB
91/CD
%/NN
by/IN
the/DT
ERRAT/NN
plot/NN
(/(
Fig/NN
./.
====================
2E/NN
)/)
showing/VBG
the/DT
well/RB
accuracy/NN
of/IN
predicted/VBN
structure/NN
./.
====================
Overall/RB
,/,
based/VBN
on/IN
the/DT
above/JJ
results/NNS
,/,
the/DT
reliability/NN
of/IN
the/DT
predicted/VBN
model/NN
was/VBD
suggested/VBN
./.
====================
Interaction/NN
study/NN
of/IN
HPV18/NN
E6/NN
with/IN
natural/JJ
ligands/NNS
through/IN
docking/NN
analysis/NN
====================
As/IN
all/DT
the/DT
natural/JJ
compounds/NNS
were/VBD
observed/VBN
to/TO
be/VB
interact/VB
with/IN
E6/NN
protein/NN
in/IN
different/JJ
conformations/NNS
and/CC
binding/NN
energy/NN
,/,
the/DT
conformation/NN
with/IN
lowest/JJS
binding/VBG
energy/NN
was/VBD
selected/VBN
for/IN
analysis/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
In/IN
case/NN
of/IN
HPV16/NN
E6/NN
protein/NN
,/,
amino/NN
acid/NN
residues/NNS
113-122/CD
(/(
CQKPLCPEEK/NN
)/)
were/VBD
associated/VBN
with/IN
p53/NN
binding/NN
[/(
38/CD
]/)
./.
====================
In/IN
our/PRP$
previous/JJ
study/NN
we/PRP
elucidated/VBD
molecular/JJ
interaction/NN
of/IN
HPV16/NN
E6/NN
proteins/NNS
with/IN
natural/JJ
inhibitors/NNS
around/IN
these/DT
p53/NN
binding/NN
site/NN
[/(
37/CD
]/)
./.
====================
Upon/IN
BLAST/NN
[/(
39/CD
]/)
sequence/NN
comparison/NN
of/IN
E6/NN
protein/NN
of/IN
HPV16/NN
and/CC
HPV18/NN
,/,
it/PRP
was/VBD
observed/VBN
that/IN
80/CD
%/NN
of/IN
the/DT
p53/NN
binding/NN
residues/NNS
,/,
conserved/VBN
in/IN
E6/NN
of/IN
HPV18/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Thus/RB
,/,
on/IN
the/DT
basis/NN
of/IN
molecular/JJ
interaction/NN
of/IN
p53/NN
binding/NN
site/NN
residues/NNS
with/IN
E6/NN
protein/NN
,/,
the/DT
active/JJ
site/NN
residues/NNS
i.e./FW
,/,
108-117/CD
(/(
CQKPLNPAEK/NN
)/)
of/IN
HPV18/NN
E6/NN
protein/NN
were/VBD
consider/RB
for/IN
docking/NN
analysis/NN
./.
====================
Fig/NN
./.
====================
4/CD
showed/VBD
best/IN
docking/NN
conformation/NN
of/IN
E6/NN
protein/NN
with/IN
twelve/JJ
ligand/NN
molecules/NNS
and/CC
the/DT
complete/JJ
interactions/NNS
were/VBD
put/RB
in/IN
Table/JJ
2/CD
./.
====================
It/PRP
was/VBD
observed/VBN
that/IN
all/DT
the/DT
ligands/NNS
were/VBD
interacting/VBG
with/IN
E6/NN
protein/NN
at/IN
p53/NN
binding/NN
site/NN
residues/NNS
./.
====================
WA/NN
was/VBD
observed/VBN
to/TO
bind/VB
with/IN
HPV18/NN
E6/NN
protein/NN
with/IN
lowest/JJS
binding/NN
energy/NN
of/IN
-5.85/CD
kcal/mol/NN
and/CC
the/DT
inhibition/NN
constant/JJ
was/VBD
found/VBN
to/TO
be/VB
51.35/CD
µM/NN
./.
====================
It/PRP
was/VBD
found/VBN
to/TO
interact/VB
with/IN
four/CD
amino/NN
acid/NN
residues/NNS
of/IN
E6/NN
(/(
Glu116/NN
,/,
Asn113/NN
,/,
Asn122/NN
,/,
and/CC
Ser140/NN
)/)
by/IN
forming/VBG
hydrogen/NN
bonds/NNS
./.
====================
Next/RB
to/TO
WA/NN
,/,
artemisinin/NN
bound/VBD
with/IN
E6/NN
protein/NN
with/IN
binding/VBG
energy/NN
of/IN
-5.68/CD
kcal/mol/NN
and/CC
inhibition/NN
constant/JJ
of/IN
68.22/CD
µM/NN
./.
====================
It/PRP
formed/VBD
only/RB
one/CD
hydrogen/NN
bonds/NNS
with/IN
the/DT
receptor/NN
at/IN
Leu112/NN
residues/NNS
./.
====================
Ursolic/JJ
acid/NN
and/CC
ferulic/JJ
acid/NN
also/RB
observed/VBN
to/TO
inhibit/VB
E6/NN
protein/NN
with/IN
good/JJ
binding/NN
affinity/NN
i.e./FW
,/,
binding/VBG
energy/NN
of/IN
-5.31/CD
and/CC
-5.18/CD
kcal/mol/NN
,/,
respectively/RB
./.
====================
Other/JJ
six/CD
natural/JJ
compounds/NNS
indol-3-carbinol/VBP
,/,
resveratrol/NN
,/,
jaceosidin/NN
,/,
berberine/JJ
,/,
EGCG/NN
,/,
and/CC
curcumin/NN
were/VBD
observed/VBN
to/TO
bind/VB
with/IN
the/DT
receptor/NN
(/(
E6/CD
protein/NN
)/)
with/IN
binding/VBG
energy/NN
range/NN
from/IN
-4.98/CD
kcal/mol/NN
to/TO
-4.08/CD
kcal/mol/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
Further/RB
,/,
other/JJ
two/CD
compounds/NNS
silymarin/NN
and/CC
gingerol/JJ
found/VBN
to/TO
interact/VB
with/IN
the/DT
receptor/NN
with/IN
less/RBR
binding/VBG
affinity/NN
i.e./FW
,/,
binding/VBG
energy/NN
of/IN
-3.67/CD
kcal/mol/NN
and/CC
-2.86/CD
kcal/mol/NN
./.
====================
Few/JJ
recent/JJ
in/IN
silico/NN
studies/NNS
are/VBP
also/RB
been/VBN
carried/VBN
out/RP
on/IN
HPV/NN
showing/VBG
the/DT
importance/NN
of/IN
computational/JJ
approach/NN
in/IN
drug/NN
designing/VBG
./.
====================
Muthukala/NN
et/FW
al/JJ
./.
====================
[/(
40/CD
]/)
observed/VBN
the/DT
inhibitory/JJ
effect/NN
of/IN
quercetin/NN
compound/NN
against/IN
human/JJ
cervical/JJ
cancer/NN
cell/NN
line/NN
proteins/NNS
through/IN
in/IN
silico/NN
docking/NN
analysis/NN
./.
====================
Kotadiya/NN
and/CC
Georrge/JJ
[/(
41/CD
]/)
identified/VBD
some/DT
putative/JJ
drugs/NNS
from/IN
natural/JJ
products/NNS
against/IN
HPV/NN
through/IN
in/IN
silico/NN
approach/NN
./.
====================
Samant/JJ
et/FW
al/JJ
./.
====================
[/(
42/CD
]/)
studied/VBN
the/DT
molecular/JJ
interactions/NNS
of/IN
human/JJ
immunodeficiency/NN
virus/NN
antiviral/JJ
drugs/NNS
against/IN
HPV18/NN
E6/NN
through/IN
in/IN
silico/NN
approach/NN
./.
====================
Mamgain/NN
et/FW
al/JJ
./.
====================
[/(
43/CD
]/)
also/RB
observed/VBN
the/DT
inhibitory/JJ
effect/NN
of/IN
natural/JJ
compounds/NNS
such/JJ
as/IN
colchine/JJ
,/,
curcumin/NN
,/,
daphnoretin/NN
,/,
ellipticine/NN
,/,
epigallocatechin-3-gallate/JJ
,/,
etc/JJ
./.
====================
against/IN
HPV16/NN
E6/NN
protein/NN
using/VBG
molecular/JJ
docking/NN
[/(
43/CD
]/)
./.
====================
In/IN
our/PRP$
study/NN
,/,
we/PRP
have/VBP
taken/VBN
12/CD
natural/JJ
compounds/NNS
,/,
reported/VBD
to/TO
be/VB
used/VBN
as/IN
an/DT
anti/JJ
cancer/NN
agent/NN
against/IN
HPV/NN
[/(
1112131415161718192021222324252627/CD
]/)
for/IN
docking/NN
analysis/NN
and/CC
observed/VBN
their/PRP$
molecular/JJ
interaction/NN
against/IN
HPV18/NN
E6/NN
./.
====================
All/DT
the/DT
natural/JJ
compounds/NNS
were/VBD
found/VBN
to/TO
interact/VB
with/IN
p53/NN
binding/NN
site/NN
residues/NNS
of/IN
HPV18/NN
E6/NN
onco-protein/NN
./.
====================
This/DT
interaction/NN
might/MD
disable/JJ
E6/NN
protein/NN
to/TO
bind/VB
with/IN
the/DT
host/NN
p53/NN
protein/NN
helping/VBG
correlate/VBP
these/DT
natural/JJ
compounds/NNS
used/VBD
as/IN
anti-cancerous/JJ
agents/NNS
to/TO
treat/VB
HPV/NN
infections/NNS
./.
====================
For/IN
treatment/NN
of/IN
different/JJ
cancers/NNS
caused/VBD
by/IN
HPV/NN
,/,
various/JJ
plant-originated/JJ
compounds/NNS
have/VBP
been/VBN
identified/VBN
and/CC
tried/VBD
as/IN
hopeful/JJ
resources/VBZ
for/IN
cancer/NN
therapy/NN
./.
====================
Due/IN
to/TO
the/DT
encroachment/JJ
in/IN
computational/JJ
biology/NN
and/CC
bioinformatics/NNS
,/,
validation/NN
of/IN
those/DT
natural/JJ
compounds/NNS
is/VBZ
possible/JJ
through/IN
computational/JJ
approach/NN
./.
====================
The/DT
E6/NN
protein/NN
of/IN
HPV6/NN
and/CC
HPV11/NN
(/(
low/JJ
risk/NN
HPVs/NNS
)/)
is/VBZ
not/RB
able/JJ
to/TO
degrade/VB
p53/NN
protein/NN
whereas/IN
in/IN
case/NN
of/IN
high/JJ
risk/NN
HPVs/NNS
(/(
HPV16/NN
and/CC
HPV18/NN
)/)
,/,
the/DT
E6/NN
protein/NN
able/JJ
to/TO
inactivate/VB
p53/NN
protein/NN
by/IN
inducing/VBG
its/PRP$
degradation/NN
./.
====================
Thus/RB
,/,
in/IN
order/NN
to/TO
design/VB
a/DT
novel/JJ
drug/NN
against/IN
cervical/JJ
cancer/NN
,/,
the/DT
HPV18/NN
E6/NN
protein/NN
can/MD
be/VB
considered/VBN
as/IN
a/DT
suitable/JJ
target/NN
./.
====================
In/IN
this/DT
study/NN
,/,
high/JJ
throughput/NN
computational/JJ
approach/NN
have/VBP
been/VBN
employed/VBN
for/IN
modeling/VBG
tertiary/JJ
structure/NN
of/IN
E6/NN
protein/NN
followed/VBN
by/IN
docking/VBG
using/VBG
AutoDock/NN
4.2/CD
./.
====================
This/DT
computational/JJ
approach/NN
needs/VBZ
to/TO
be/VB
explored/VBN
further/RBR
in/IN
order/NN
to/TO
design/VB
novel/JJ
drugs/NNS
against/IN
cervical/JJ
cancer/NN
from/IN
natural/JJ
resources/VBZ
./.
====================
Chemical/JJ
structure/NN
of/IN
natural/JJ
compounds/NNS
./.
====================
(/(
A/NN
)/)
Artemisinin/NN
./.
====================
(/(
B/NN
)/)
Withaferin/NN
A/NN
./.
====================
(/(
C/NN
)/)
Ursolic/JJ
acid/NN
./.
====================
(/(
D/NN
)/)
Ferulic/JJ
acid/NN
./.
====================
(/(
E/NN
)/)
(/(
-/:
)/)
-Epigallocatechin-3-gallate/JJ
./.
====================
(/(
F/NN
)/)
Berberin/NN
./.
====================
(/(
G/NN
)/)
Resveratrol/NN
./.
====================
(/(
H/NN
)/)
Jaceosidin/NN
./.
====================
(/(
I/NN
)/)
Curcumin/NN
./.
====================
(/(
J/NN
)/)
Gingerol/NN
./.
====================
(/(
K/NN
)/)
Indol-3-carbinol/NN
./.
====================
(/(
L/NN
)/)
Silymarin/NN
./.
====================
(/(
A/NN
)/)
3D/NN
structure/NN
of/IN
predicted/VBN
human/JJ
papillomavirus/NN
(/(
HPV/NN
)/)
18/CD
E6/NN
model/NN
./.
====================
(/(
B/NN
)/)
Ramachandran/NN
plot/NN
of/IN
predicted/VBN
E6/NN
model/NN
(/(
The/DT
red/JJ
,/,
dark/VBP
yellow/RB
,/,
and/CC
light/JJ
yellow/RB
regions/NNS
represent/VBP
the/DT
most/JJS
favored/VBD
,/,
allowed/VBD
,/,
and/CC
generously/RB
allowed/VBD
regions/NNS
)/)
./.
====================
(/(
C/NN
)/)
ProSA-web/NN
Z-scores/NNS
of/IN
all/DT
protein/NN
chains/NNS
in/IN
Protein/NN
Data/NNS
Bank/NN
(/(
PDB/NN
)/)
determined/VBN
by/IN
X-ray/NN
crystallography/NN
(/(
light/NN
blue/JJ
)/)
and/CC
nuclear/JJ
magnetic/JJ
resonance/NN
spectroscopy/NN
with/IN
respect/NN
to/TO
their/PRP$
length/NN
./.
====================
The/DT
Z-score/JJ
of/IN
E6/NN
was/VBD
present/JJ
in/IN
that/DT
range/NN
represented/VBN
in/IN
black/JJ
dot/JJ
./.
====================
(/(
D/NN
)/)
Energy/NN
plot/NN
for/IN
the/DT
predicted/VBN
E6/NN
of/IN
HPV18/NN
./.
====================
(/(
E/NN
)/)
ERRAT/NN
plot/NN
for/IN
residue-wise/JJ
analysis/NN
of/IN
homology/NN
model/NN
./.
====================
Sequence/NN
alignment/NN
results/NNS
of/IN
E6/NN
protein/NN
of/IN
human/JJ
papillomavirus/NN
(/(
HPV/NN
)/)
18/CD
and/CC
HPV16/NN
showing/VBG
conserved/VBN
p53/NN
binding/NN
site/NN
residues/NNS
./.
====================
Interaction/NN
profile/NN
of/IN
E6/NN
with/IN
natural/JJ
ligands/NNS
./.
====================
(/(
A/NN
)/)
Withaferin/NN
A/NN
./.
====================
(/(
B/NN
)/)
Artemisinin/NN
./.
====================
(/(
C/NN
)/)
Ursolic/JJ
acid/NN
./.
====================
(/(
D/NN
)/)
Ferulic/JJ
acid/NN
./.
====================
(/(
E/NN
)/)
Indol-3-carbinol/NN
./.
====================
(/(
F/NN
)/)
Resveratrol/NN
./.
====================
(/(
G/NN
)/)
Jaceosidin/NN
./.
====================
(/(
H/NN
)/)
Berberin/NN
./.
====================
(/(
I/NN
)/)
(/(
-/:
)/)
-Epigallocatechin-3-gallate/JJ
./.
====================
(/(
J/NN
)/)
Curcumin/NN
./.
====================
(/(
K/NN
)/)
Silymarin/NN
./.
====================
(/(
L/NN
)/)
Gingerol/NN
showing/VBG
interaction/NN
of/IN
ligands/NNS
with/IN
the/DT
active/JJ
site/NN
residues/NNS
of/IN
E6/NN
by/IN
forming/VBG
hydrogen/NN
bonds/NNS
./.
====================
Natural/JJ
compounds/NNS
reported/VBD
to/TO
use/VB
against/IN
HPV/NN
infection/NN
====================
Polar/JJ
contacts/NNS
information/NN
from/IN
docking/NN
calculation/NN
between/IN
ligands/NNS
and/CC
protein/NN
====================
